MT Newswires on MSN5mon
Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist SaysScholar Rock said in a conference call late Monday that it plans to initiate a study for the treatment for patients under 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback